TABLE 1.
Baseline characteristics for all study groups
| GROUP | HCC | BLD | CGC | HCs | OGTLM |
|---|---|---|---|---|---|
| N | 145 | 57 | 55 | 101 | 112 |
| Gender n(%) | |||||
| Male | 121(83.4%) | 14(24.6%) | 26(47.3%) | 44(43.6%) | 81(72.3%) |
| Female | 24(16.6%) | 43(75.4%) | 29(52.7%) | 57(56.4%) | 31(27.7) |
| Age(years) | 58.9 ± 10.8 | 48.1 ± 11.6 | 64 ± 10.3 | 39.8 ± 11.3 | 58.7 ± 10.3 |
| PIVKA‐II (mAU/ml) | 1068.54(152.26 ~ 8049.18) | 23.11(19.15 ~ 28.58) | 28.95(19.75 ~ 75.17) | 25.22(21.42 ~ 31.67) | 32.19(25.08 ~ 42.57) |
| AFP (ng/ml) | 52.8(6.15 ~ 1546.6) | 1.9(1.05 ~ 2.85) | 2.4(1.1 ~ 3.9) | 1.7(0.85 ~ 3.0) | 2.8(1.93 ~ 4.9) |
Abbreviations: AFP, alpha‐fetoprotein; BLD, benign liver disease; CGC, cholangiocarcinoma and gallbladder carcinoma; HCC, hepatocellular carcinoma; HCs, healthy controls; N, number of patients; OGTLM, other gastrointestinal tumors with liver metastasis, PIVKA‐II, prothrombin induced by vitamin K absence II.